Author Archives: Marina

Citation Number Limits in PubMed

Posted on by

When handling search results in PubMed a user may encounter a situation when some operations are limited to a certain number of citations. While some users may think that, in practice, they will never need to deal with a very large number of citations, such situations do occur.

Below are instances when PubMed users will encounter a limit to the number of citations (and Pubmed messages alerting to that):

  • When browsing a lengthy list of search results or jumping to a page towards the end of a search results list (This site can display up to 10,000 results. Please see the User Guide for more information on navigating your search results.)
  • When saving citations to file (Only the first 10,000 citations will be saved in your file.)
  • When e-mailing your citations (Only the first 1,000 citations will be sent in your email. You will receive citations in multiple emails.)
  • When adding citations to a Collection in My NCBI account: (Only the first 1,000 citations will be added to collection.)
  • When sending citations to Clipboard (Only the first 500 items will be sent to clipboard.)

These problems can be addressed with the following options:

Other databases, such as Embase, CINAHL, Scopus, Web of Science, have similar, but not exactly the same maximums of the number of citations allowed for certain operations.

How To Receive Weekly Emails from The Cancer Letter

Posted on by

The Cancer Letter is “an independent weekly news publication” that provides information on “the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health”.

The MSK Library provides an institutional subscription to this publication. If you would like to receive email alerts, please follow these instructions to subscribe via email:

1. From the Library Website, in ONESEARCH, type Cancer Letter or click on the link to The Cancer Letter under eJournals
2. When prompted, authenticate by entering your MSK login credentials
3. Scroll down the page and click on News Alerts in the page footer (black bar)
4. Enter your name and email address and click Submit
5. You may need to click on the link in the email if you receive it to confirm subscription.

For more information on related publications and setting up journal alerts, email Ask-A-Librarian or call the general reference line at 212.639.7439.

Bacterial Based Cancer Immunotherapy, Prostate Cancer and Diet, and More

Posted on by
  • Australian researchers conducted animal studies and a phase 1 clinical trial on human cancer patients by administering dead bacteria directly into the tumor so that the body’s immune response to bacteria helps kill cancerous cells. The injected substance contained dissolved killed mycobacteria. Once the immune response has been triggered, the immune system starts attacking both cancer cells at the injection site (e.g., the tumor itself) and metastases. This treatment, if implemented, may require only a few injections, cause minimal side effects and be cheaper than most current therapies. The idea of such treatment is not new, but this was the first human study based on it. Phase 2 clinical trial is pending. The research was published in Journal for ImmunoTherapy of Cancer.
  • A similar approach was taken by a group of scientists from the U.K. and China. They injected, into solid tumors, a common parasite called Toxoplasma gondii, which they modified to limit its growth ability. They tried this approach on several cancer types in animals. These direct intra-tumoral injections boosted anti-tumor immunity in the case of so-called cold tumors (tumors that are not typically associated with strong immune response) by increasing the effectiveness of checkpoint inhibition therapy. The study was also published in Journal for ImmunoTherapy of Cancer
  • Researchers from Cleveland Clinic used data from a randomized clinical trial to analyze the relationship between prostate cancer, diet, and the gut microbiome. The study found associations between prostate cancer’s aggressiveness and three metabolites – phenylacetylglutamine, choline, and betaine, – which are found in some common foods or are amino-acids’ products broken down by gut bacteria. As in any epidemiological study, while having established the association, this research does not prove causation. Nevertheless, this study contributes to the knowledge of the interplay between diet, gut microbiome, and prostate cancer. The study was published in Cancer Epidemiology, Biomarkers and Prevention.
  • Yet another study looked at the association between gut bacteria and prostate cancer. It established that gut bacteria might drive androgen production and contribute to prostate cancer resistance to treatment. The study lays a foundation to explore the role of such microbes as potential therapeutic targets. The study was published in Science
  • A new study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate cancer. This finding is especially important for fighting the drug resistance propensity of prostate cancer. The study was published in Cancer Research
  • João Pedro de Magalhães, a microbiologist from the University of Liverpool in the UK, conducted the research into the body of publications related to genes in the context of cancer. By researching the related content in PubMed, he found that most genes (nearly 9 in 10 human genes) have been mentioned in association with cancer in the published studies. The author offers his opinion to the biomedical community not to scatter their attention by focusing on every gene’s association with cancer, as some of such associations could be more casual than not, but to focus on the most important genes that truly drive cancer development. The article was published in Trends In Genetics.